Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound) as part of the SURMOUNT-5 study, and then switched to orforglipron or placebo for a 52-week maintenance phase. Orforglipron met all primary and key secondary endpoints and has now been submitted to the U.S. Food and Drug Administration for regulatory review as an obesity treatment.
What this reveals about treatment transitions in chronic obesity care
The ATTAIN-MAINTAIN trial addresses a clinically relevant question that often arises in real-world obesity care: what options exist for patients after the initial weight loss phase on injectable incretin therapy? While semaglutide and tirzepatide have both demonstrated substantial weight reduction, questions remain about long-term adherence, tolerability, and sustainability. These injectables, though effective, may lose favor with patients due to administration burden, side effects, or insurance access challenges over time.
Orforglipron was tested precisely in this context. It was administered to patients who had already achieved weight loss plateaus after more than a year on maximum tolerated doses of semaglutide or tirzepatide. In doing so, Eli Lilly and Company positioned orforglipron not as a replacement for GLP-1 injectables, but as a maintenance therapy that could offer a more convenient, daily oral format for long-term disease management. The observed differences in weight regain between the orforglipron and placebo arms suggest that patients switching to orforglipron were able to preserve nearly all of their prior weight loss gains.
Specifically, patients switching from Wegovy to orforglipron regained only 0.9 kilograms over 52 weeks, while those switching from Zepbound regained about 5.0 kilograms. This contrasts sharply with patients who switched to placebo, who regained 9.4 kilograms and 9.1 kilograms respectively in post-hoc 24-week analyses prior to rescue therapy initiation. These differences are not only statistically significant but may also carry clinical and psychological weight for patients seeking to sustain their efforts.
Why oral GLP-1 delivery is more than just a convenience story
Orforglipron is unique among GLP-1 receptor agonists because it is a non-peptide small molecule designed to be taken orally at any time of day, without food or fluid restrictions. That formulation differentiates it from oral semaglutide, which requires fasting and has not been approved for obesity. The convenience profile of orforglipron could make it more attractive for long-term adherence, especially among patients reluctant to continue weekly injections after achieving a weight plateau.
Eli Lilly and Company licensed orforglipron from Chugai Pharmaceutical Co., Ltd. in 2018 and has continued to expand its clinical program with multiple indications under investigation. These include not only weight management and type 2 diabetes but also conditions such as obstructive sleep apnea, hypertension, knee osteoarthritis, and stress urinary incontinence in patients with obesity. This suggests that the company views orforglipron not only as a maintenance drug, but as a multi-indication metabolic platform potentially capable of addressing the downstream comorbidities that often follow or accompany obesity.
The simplicity of orforglipron’s administration could also enable broader primary care adoption, provided its safety and tolerability profile remains favorable in larger patient cohorts. In the ATTAIN-MAINTAIN trial, the most common side effects were gastrointestinal in nature and generally mild or moderate. Discontinuation rates due to adverse events remained below 8 percent across all arms, with no liver-related safety signals reported. This safety consistency with previous orforglipron studies may support a smoother regulatory path and easier payer adoption if cost-effectiveness models hold up.
How the trial design reflects real-world therapeutic needs
What makes ATTAIN-MAINTAIN particularly notable is its design rooted in real-world treatment dynamics. Participants had to have achieved a weight plateau in the prior SURMOUNT-5 trial, defined as less than 5 percent change in body weight between weeks 60 and 72 on injectable GLP-1 or GIP/GLP-1 therapy. This ensured that patients were not still actively losing weight, and thus the study truly evaluated the capacity of orforglipron to prevent rebound after withdrawal from highly effective injectables.
The trial also incorporated a rescue protocol where patients who regained 50 percent or more of their prior weight loss were offered open-label orforglipron therapy. This element adds a layer of patient-centric ethics to the design and recognizes that weight regain can be demoralizing or clinically risky. Such pragmatism in trial design may help support broader physician buy-in and aligns with emerging expectations for long-term obesity management that go beyond static endpoints like percent weight loss.
The dosing strategy in the study was also carefully aligned with clinical practice. Patients titrated from a starting dose of 12 milligrams up to either 24 milligrams or 36 milligrams depending on individual tolerability, mirroring the flexible titration schedules often required with incretin-based therapies.
What regulatory and payer dynamics could shape orforglipron’s uptake
While the data from ATTAIN-MAINTAIN strengthens the clinical case for orforglipron, its ultimate adoption will depend on how regulators and payers interpret the trial’s scope and relevance. Because the study only enrolled patients who had previously succeeded on semaglutide or tirzepatide, the findings do not necessarily demonstrate orforglipron’s efficacy as a first-line agent for weight loss. The U.S. Food and Drug Administration may choose to approve it specifically as a maintenance therapy or require additional data for broader obesity indications.
Payers may also view orforglipron through the lens of treatment sequencing. Questions around whether coverage will be restricted to patients previously on injectable GLP-1 therapy, or whether orforglipron can be prescribed independently, are likely to influence its market potential. If insurers classify the oral therapy as a step-down or continuation option, access could hinge on prior authorization pathways and cost-effectiveness models comparing it to extended use of injectable treatments.
The fact that Eli Lilly and Company is already pursuing multiple obesity-related indications for orforglipron suggests an intention to build a modular label that addresses both treatment and maintenance phases, much like how insulin regimens evolved in diabetes care. Still, broader acceptance will depend on how well orforglipron performs outside of this tightly defined trial population.
Why orforglipron may be a strategic bridge in Lilly’s metabolic portfolio
The success of orforglipron may also be viewed as a portfolio retention strategy by Eli Lilly and Company. As generic erosion, price pressure, and patient fatigue begin to impact first-generation GLP-1s, pharmaceutical companies are increasingly exploring pipeline assets that can extend duration of therapy and maintain customer lifetime value. By offering an oral follow-on therapy to injectable GLP-1 users, Lilly could create a sequential care model that captures patients throughout their obesity journey, from initial loss to long-term stabilization and comorbidity prevention.
This strategic layering may also provide insulation from competitive threats. Companies such as Novo Nordisk, Pfizer, and Amgen are developing their own oral GLP-1 or GIP/GLP-1 programs, some of which are advancing rapidly. By positioning orforglipron as a post-injectable bridge rather than a direct competitor, Eli Lilly and Company may avoid the head-on comparison trap while still anchoring its metabolic franchise in the expanding obesity market.
As obesity increasingly becomes viewed as a chronic, relapsing condition that requires multi-year pharmaceutical support, the industry is moving beyond short-term trials and toward integrated therapeutic ecosystems. Orforglipron is arguably the first oral GLP-1 candidate to fully embrace this shift by explicitly targeting the maintenance gap that has thus far gone under-addressed in both research and reimbursement strategies.
Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →